{"id":7470,"date":"2025-06-25T17:17:01","date_gmt":"2025-06-25T14:17:01","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7470"},"modified":"2025-06-25T17:17:01","modified_gmt":"2025-06-25T14:17:01","slug":"summary-first-commercial-approval-of-a-polymer-heart-valve-tria-mitral-valve","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/summary-first-commercial-approval-of-a-polymer-heart-valve-tria-mitral-valve\/","title":{"rendered":"Summary:\u00a0 First Commercial Approval of a Polymer Heart Valve (Tria Mitral Valve)."},"content":{"rendered":"<div>Summary:<\/div>\n<div>First Commercial Approval of a Polymer Heart Valve (Tria Mitral Valve).<\/div>\n<div>The device received approval in India, announced on June 5, 2025, following positive clinical data first presented at the New York Valves Summit in 2024\u2014marking a major step forward in polymer valve technology.<\/div>\n<div><\/div>\n<div><span> 1. Historic Milestone:<\/span><\/div>\n<div><span> \u2022 Foldax\u2019s Tria mitral valve, made from proprietary LifePolymer, has received commercial approval in India\u2014the first-ever regulatory approval for a polymer heart valve globally.<\/span><\/div>\n<div><span> 2. Material and Design:<\/span><\/div>\n<div><span> \u2022 The valve is animal tissue-free and robotically manufactured to match each patient\u2019s native mitral anatomy.<\/span><\/div>\n<div><span> \u2022 LifePolymer is engineered to resist calcification and degradation, enhancing long-term durability.<\/span><\/div>\n<div><span> 3. Anticoagulation Needs:<\/span><\/div>\n<div><span> \u2022 Tria is expected to require anticoagulant only for a short period after surgery, similar to tissue valves, offering a safer option for many patients\u2014especially those who cannot tolerate lifelong anticoagulation.<\/span><\/div>\n<div><span> 4. Durability Expectations:<\/span><\/div>\n<div><span> \u2022 While long-term data is still being gathered, the valve is expected to have a lifespan of 15\u201320 years or more, based on its resistance to structural degeneration.<\/span><\/div>\n<div><span> 5. Clinical Trial Data:<\/span><\/div>\n<div><span> \u2022 Approval was supported by clinical data from 67 patients (ages 19\u201367), mostly women, presented at New York Valves 2024.<\/span><\/div>\n<div><span> \u2022 Results showed good short-term outcomes and potential for broad applicability, including in young adults and women of childbearing age.<\/span><\/div>\n<div><span> 6. Manufacturing and Partnership:<\/span><\/div>\n<div><span> \u2022 The Tria valves will be locally manufactured in India by Dolphin Life Sciences.<\/span><\/div>\n<div><span> 7. Future Expansion:<\/span><\/div>\n<div><span> \u2022 Foldax aims to extend the LifePolymer and robotic manufacturing platform to additional structural heart applications, including transcatheter valve technologies and other valve positions.<\/span><\/div>\n<div><span> 8. U.S. Regulatory Status:<\/span><\/div>\n<div><span> \u2022 The Tria valve has not yet received FDA approval for commercial use in the United States.<\/span><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/cardiovascularnews.com\/tria-polymer-mitral-valve-gains-indian-cdsco-approval\/\">https:\/\/cardiovascularnews.com\/tria-polymer-mitral-valve-gains-indian-cdsco-approval\/<\/a><\/div>\n<div><\/div>\n<div><a href=\"https:\/\/cardiovascularbusiness.us13.list-manage.com\/track\/click?u=ede357a4dde4e6d1363fede03&amp;id=3b257dd13d&amp;e=e8ff1dad3e\">https:\/\/cardiovascularbusiness.us13.list-manage.com\/track\/click?u=ede357a4dde4e6d1363fede03&amp;id=3b257dd13d&amp;e=e8ff1dad3e<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Summary: First Commercial Approval of a Polymer Heart Valve (Tria Mitral Valve). The device received approval in India, announced on June 5, 2025, following positive clinical data first presented at the New York Valves Summit in 2024\u2014marking a major step forward in polymer valve technology. 1. Historic Milestone: \u2022 Foldax\u2019s Tria mitral valve, made from [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7470","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7470","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7470"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7470\/revisions"}],"predecessor-version":[{"id":7477,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7470\/revisions\/7477"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7470"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7470"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}